Ricevi le ultime notizie sulle azioni Kala Bio con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di KALA

Ultime notizie per

KALA BIO INC

Kala Bio

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Kala Bio Inc

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics Inc

KALAMAZOO RESOURCES by KALAMAZOO RESOURCES LTD.

Kalamazoo Resources Ltd

Kalao

Earnings

Press Releases

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update

News

KALA BIO to Present at Jefferies Global Healthcare Conference

Health Care

KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Management

KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference

General

KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint

KALA

AIM ImmunoTech

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Ensysce Biosciences

Genprex

GRI Bio

GT Biopharma

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Mainz Biomed

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revolution Medicines

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Comments

Kala Bio Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO